The mutation freezes a crucial protein called epidermal growth factor receptor in the "on" position.
All three drugs target the epidermal growth factor receptor (EGFR), a protein that is over-expressed in cancer cells.
Drugs like Iressa target a protein called the epidermal growth factor receptor (EGFR), which tells cells when to divide.
One reason could be that epidermal growth factor, the protein Iressa blocks, wasn't the right one to begin with.
The process, called a cultured epidermal autograft, was done more than 100 times in the United States last year, according to Genzyme.
Both pills inhibit a receptor for a protein called the epidermal growth factor (EGF) that many tumors seem to depend upon to grow.
The molecule - epidermal growth factor receptor (EGFR) - relays instructions to cells to grow and divide, and to ignore signals telling them to die.
Hunting for other targets in the early 1980s, he focused on a protein called epidermal growth factor, or EGF, then a hot area of research.
Lapatinib, it turns out, also inhibits the activity of a protein called the epidermal growth factor receptor, which has been found to be important for stem-cell proliferation.
The public has mostly focused on Erbitux's ability to slow tumor growth by blocking epidermal growth factor receptor, a key growth-promoting protein that is overabundant in many cancer cells.
The new technology, called an epidermal electronic system (EES), is based on a new class of micro-electronics that integrates miniature sensors, light-emitting diodes, tiny transmitters and refined wire-filament receivers.
The drugs are the product of more than three decades of research into EGF, so named for an ability to stimulate the growth of skin (epidermal) cells in normal tissue.
应用推荐